Developments in therapy with monoclonal antibodies and related proteins
H Michael Shepard, Gail Lewis Phillips, Christopher D Thanos and Marc Feldmann
DOI: https://doi.org/10.7861/clinmedicine.17-3-220
Clin Med June 2017 H Michael Shepard
AHalozyme, San Diego, USA
Roles: research fellow
Gail Lewis Phillips
BGenentech Inc, San Francisco, USA
Roles: senior scientist
Christopher D Thanos
CNew Molecule Discovery, Halozyme, San Diego, USA
Roles: senior director
Marc Feldmann
DKennedy Institute of Rheumatology, Oxford, UK
Roles: emeritus professor
Article Information
vol. 17 no. 3 220-232
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Published online June 1, 2017.
Copyright & Usage:
© Royal College of Physicians 2017. All rights reserved.
Author Information
- H Michael Shepard, research fellowA,
- Gail Lewis Phillips, senior scientistB,
- Christopher D Thanos, senior directorC and
- Marc Feldmann, emeritus professorD⇑
- AHalozyme, San Diego, USA
- BGenentech Inc, San Francisco, USA
- CNew Molecule Discovery, Halozyme, San Diego, USA
- DKennedy Institute of Rheumatology, Oxford, UK
- Address for correspondence: Professor Sir Marc Feldman, Kennedy Institute of Rheumatology, Botnar Research Centre, Nuffield Dept of Rheumatology Orthopedics and Musculoskeletal Science, University of Oxford, Windmill Road, Headington, Oxford OX3 7LD. Email: marc.feldmann{at}kennedy.ox.ac.uk
Article usage
Article Tools
Developments in therapy with monoclonal antibodies and related proteins
H Michael Shepard, Gail Lewis Phillips, Christopher D Thanos, Marc Feldmann
Clinical Medicine Jun 2017, 17 (3) 220-232; DOI: 10.7861/clinmedicine.17-3-220
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- ioSearch: a tool for searching disease-associated interacting omics; application on breast cancer data
- Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
- Single-domain antibodies represent novel alternatives to monoclonal antibodies as targeting agents against the human papillomavirus 16 E6 protein
- Targeting limited NHS resources to affect optimal care